Yates, Tom A;
Grint, Daniel J;
(2025)
Primary efficacy endpoints in phase 3 non-inferiority trials to establish new tuberculosis treatment regimens should only include microbiological outcomes.
The Lancet Microbe
, Article 101117. 10.1016/j.lanmic.2025.101117.
(In press).
Preview |
PDF
Yates and Grint - microbiological outcomes in TB trials.pdf - Published Version Download (94kB) | Preview |
| Type: | Article |
|---|---|
| Title: | Primary efficacy endpoints in phase 3 non-inferiority trials to establish new tuberculosis treatment regimens should only include microbiological outcomes |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/j.lanmic.2025.101117 |
| Publisher version: | https://doi.org/10.1016/j.lanmic.2025.101117 |
| Language: | English |
| Additional information: | Copyright © 2025 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/ 4.0/). |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Infection and Immunity |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10206194 |
Downloads since deposit
Loading...Download activity - last month
Loading...Download activity - last 12 months
Loading...Downloads by country - last 12 months
Loading...Archive Staff Only
 |
View Item |
